FDA/CDC

FDA class I recall for some Cordis carotid stent systems


 

Cordis, part of Cardinal Health, has recalled certain lots of its Precise PRO Rx carotid stent system because of a risk of separation of the distal tip of the sheathed delivery system during use.

The Food and Drug Administration has classified this recall as class I, the most serious type, because of the potential for serious injury or death.

“If the device separates during use this may cause serious adverse events such as removal of the separated tip from the carotid artery, embolization distally, or stroke,” noted the recall notice posted on the FDA website.

To date, there have been seven complaints, including five reported injuries, related to this device issue. No deaths have been reported.

The Precise PRO Rx stent system is used in patients with stenotic lesions of the carotid arteries. The system includes a metal (nitinol) self-expanding stent preloaded on a delivery catheter used to place the stent.

The recall covers 7,300 devices made between October 2019 and August 2020 and distributed between Dec. 6, 2019, to Feb. 8, 2021.

The FDA has a complete list of product and lot numbers for the recalled devices on their website.

The company sent an urgent medical device recall letter to all affected customers asking them to check inventories and providing instructions on how to return any recalled product they have on hand.

Health care providers with questions about this recall can contact the company by email at GMB-FieldCorrectiveActionp@cardinalhealth.com or by phone at 786-313-2087.

Health care providers can report adverse reactions or quality problems they experience using these devices to the FDA’s MedWatch program.

A version of this article first appeared on Medscape.com.

Recommended Reading

Newer iPhones disable implanted defibrillators
Journal of Clinical Outcomes Management
DOACs offered after heart valve surgery despite absence of data
Journal of Clinical Outcomes Management
Colchicine before PCI for acute MI fails to improve major outcomes
Journal of Clinical Outcomes Management
FDA okays transcatheter pulmonary valve for congenital heart disease
Journal of Clinical Outcomes Management
Detroit cardiologists prevail in retaliation suit against Tenet
Journal of Clinical Outcomes Management
TAVR feasible, comparable with surgery in rheumatic heart disease
Journal of Clinical Outcomes Management
OCS heart system earns hard-won backing of FDA panel
Journal of Clinical Outcomes Management
Cardiologists can perform stroke thrombectomy to fill ‘unmet need’
Journal of Clinical Outcomes Management
PTSD linked to ischemic heart disease
Journal of Clinical Outcomes Management
COVID plus MI confers poor prognosis; 1 in 3 die in hospital
Journal of Clinical Outcomes Management